Literature DB >> 25541241

Phagocytic activity of monocytes, their subpopulations and granulocytes during post-transplant adverse events after hematopoietic stem cell transplantation.

Michaela Döring1, Karin Melanie Cabanillas Stanchi2, Annika Erbacher2, Susanne Haufe2, Carl Philipp Schwarze2, Rupert Handgretinger2, Michael Hofbeck3, Gunter Kerst4.   

Abstract

Phagocytosis of granulocytes and monocytes presents a major mechanism that contributes to the clearance of pathogens and cell debris. We analyzed the phagocytic activity of the peripheral blood cell monocytes, three monocyte subpopulations and granulocytes before and up to one year after hematopoietic stem cell transplantation, as well as during transplant-related adverse events. 25 pediatric patients and young adults (median age of 11.0 years) with hemato-oncological malignancies and non malignancies were enrolled in the prospective study. Ingestion of fluorescence-labeled Escherichia coli bacteria was used to assess the phagocytic activity of monocytes and their subpopulations and granulocytes by means of flow cytometry in the patient group as well as in a control group (n=36). During sepsis, a significant increase of phagocytic activity of monocytes (P=0.0003) and a significant decrease of the phagocytic activity of granulocytes (P=0.0003) and the CD14+ CD16++ monocyte subpopulation (P=0.0020) occurred. At the onset of a veno-occlusive disease, a significant increase of phagocytic activity in the CD14++ CD16+ monocyte subpopulation (P=0.001) and a significant decrease in the phagocytic activity of the CD14++ CD16- monocyte subpopulation (P=0.0048) were observed. In conclusion, the phagocytic activity of monocytes, their subpopulations and granulocytes might be a useful and easy determinable parameter that enables identification of post-transplant complications after hematopoietic stem cell transplantation. The alterations of phagocytic activity contribute to the altered immune response that accompanies adverse events after hematopoietic stem cell transplantation.
Copyright © 2014 Elsevier GmbH. All rights reserved.

Entities:  

Keywords:  Hematopoietic stem cell transplantation; Monocyte subpopulations; Monocytes; Pediatric patients; Phagocytic activity; Post-transplant complications

Mesh:

Substances:

Year:  2014        PMID: 25541241     DOI: 10.1016/j.imbio.2014.12.002

Source DB:  PubMed          Journal:  Immunobiology        ISSN: 0171-2985            Impact factor:   3.144


  6 in total

1.  Vibrio metschnikovii, a Potential Pathogen in Freshwater-Cultured Hybrid Sturgeon.

Authors:  Zidong Xiao; Xudong Li; Mingyang Xue; Mengwei Zhang; Wei Liu; Yuding Fan; Xihua Chen; Zhipeng Chu; Feilong Gong; Lingbing Zeng; Yong Zhou
Journal:  Animals (Basel)       Date:  2022-04-24       Impact factor: 3.231

Review 2.  Determinants of Phagosomal pH During Host-Pathogen Interactions.

Authors:  Johannes Westman; Sergio Grinstein
Journal:  Front Cell Dev Biol       Date:  2021-01-11

3.  Production of IL-6 and Phagocytosis Are the Most Resilient Immune Functions in Metabolically Compromised Human Monocytes.

Authors:  Pierre-Louis Krauss; Moritz Pfeiffenberger; Alexandra Damerau; Thomas Buttgereit; Yuling Chen; Timo Gaber; Frank Buttgereit
Journal:  Front Immunol       Date:  2021-10-19       Impact factor: 7.561

Review 4.  Uncovering the multifaceted roles played by neutrophils in allogeneic hematopoietic stem cell transplantation.

Authors:  Cristina Tecchio; Marco Antonio Cassatella
Journal:  Cell Mol Immunol       Date:  2020-11-17       Impact factor: 11.530

5.  Oxidative burst and phagocytic activity of phagocytes in canine parvoviral enteritis.

Authors:  Kelly du Preez; Yolandi Rautenbach; Emma H Hooijberg; Amelia Goddard
Journal:  J Vet Diagn Invest       Date:  2021-06-19       Impact factor: 1.569

Review 6.  Phagocytosis-Inflammation Crosstalk in Sepsis: New Avenues for Therapeutic Intervention.

Authors:  Marcela Hortová-Kohoutková; Federico Tidu; Marco De Zuani; Vladimír Šrámek; Martin Helán; Jan Frič
Journal:  Shock       Date:  2020-11       Impact factor: 3.533

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.